Core Viewpoint - Allarity Therapeutics has successfully dismissed a securities class action lawsuit, allowing the company to refocus on advancing its cancer treatment, stenoparib, and its companion diagnostic technology, the Drug Response Predictor (DRP) [1][2][3]. Company Overview - Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing personalized cancer treatments, particularly stenoparib, a dual-targeted inhibitor for advanced ovarian cancer [6]. - The company utilizes its proprietary DRP technology to identify patients who are most likely to benefit from stenoparib, enhancing the therapeutic benefit rate [5][6]. Legal Proceedings - The lawsuit, filed on September 13, 2024, alleged misleading statements regarding the regulatory prospects of the Dovitinib New Drug Application (NDA) [2]. - The case has been dismissed in its entirety, with no settlement or payment made by Allarity or its officers [2]. Product Information - Stenoparib is an orally available small-molecule inhibitor targeting PARP1/2 and tankyrase 1/2, showing potential in treating various cancers, including ovarian cancer [4]. - The DRP platform has demonstrated the ability to predict clinical outcomes from drug treatments in cancer patients, based on gene expression profiles from patient biopsies [5]. Future Focus - Following the dismissal of the lawsuit, the company aims to concentrate on advancing stenoparib and its companion diagnostic through a new Phase 2 trial protocol for advanced ovarian cancer [3][8].

Patient enrollment set to begin at leading U.S. clinical trial sites, new drug product already deliveredTrial will advance stenoparib and the stenoparib-DRP Companion Diagnostic toward FDA approvalTwo patients in the ongoing phase 2 trial have now exceeded 17 months on stenoparib treatment Boston (February 24, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt path ...

Core Viewpoint - Allarity Therapeutics is advancing the clinical development of stenoparib, a dual PARP/Wnt pathway inhibitor, towards FDA approval for advanced ovarian cancer, utilizing its Drug Response Predictor (DRP) technology for patient selection [1][2][4]. Group 1: Clinical Development Plans - The new Phase 2 protocol aims to optimize the dose of stenoparib and refine DRP patient selection criteria to maximize clinical benefits [1][2]. - The trial will focus on patients with advanced, recurrent, platinum-resistant ovarian cancer, a group that has shown durable clinical benefits from stenoparib [2][4]. - Patient enrollment is expected to begin in the first half of 2025, pending final protocol review by regulatory authorities [5][6]. Group 2: Mechanism of Action and Therapeutic Potential - Stenoparib is a small-molecule inhibitor targeting PARP1/2 and tankyrase 1/2, with potential implications for controlling the Wnt pathway, which is involved in various cancers [7]. - The trial is designed to enhance understanding of stenoparib's therapeutic mechanism, particularly its impact on the Wnt pathway [2][3]. Group 3: Drug Response Predictor (DRP) Technology - The DRP technology will be used to identify patients most likely to benefit from stenoparib, generating a robust data set to refine the DRP cut-off [3][9]. - The DRP platform has shown significant predictive ability for clinical outcomes in cancer patients across numerous studies [9]. Group 4: Company Background - Allarity Therapeutics is focused on developing personalized cancer treatments and has exclusive global rights for the development and commercialization of stenoparib [10]. - The company is headquartered in the U.S. and has a research facility in Denmark, addressing significant unmet medical needs in cancer treatment [10].

Boston (January 30, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selection technology, has filed a Form 8-K with the U.S. Securities and Exchange Commission ("SEC") regarding its agreement in principle with the SEC staff to resolve the previously disclosed SEC investigation. The settlement relates to the Company's disclosures, ...

Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib’s clinical development toward FDA approval Expansion of Allarity Medical Laboratory into revenue-generating services for external biotech clientsContinued focus on advancing stenoparib to address critical unmet needs in ovarian cancer Boston (November 18, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASD ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share ALLR The Nasdaq Stock Market LLC Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30 ...

Exhibit 99.1 Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights - Cash balance at $18.5 million - Strengthened leadership team with new members driving stenoparib development - NASDAQ compliance regained Boston (November 14, 2024)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments using its proprietary, drug-specific patient selectio ...

NEW YORK, Nov. 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Allarity Therapeutics, Inc. (NASDAQ: ALLR) between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”), of the important November 12, 2024 lead plaintiff deadline. SO WHAT: If you purchased Allarity securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Allarity securities between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”). I ...